- Trial Phase
- Phase 1b/2
- Time to Market
- If Phase 1b/2 HCC data is positive (2H 2026), a registrational Phase 3 trial would likely follow, putting potential approval several years out (~2029+). Fast Track designation may accelerate timelines modestly.
- Why 7/10
- The next hard catalyst is topline data from the Phase 1b/2 REVERT LIVER CANCER trial of TTI-101 in hepatocellular carcinoma (HCC), expected in 2H 2026 (within ~6 months). This is the company's lead value driver since the IPF program failed. With only ~$25M cash runway through Q4 2026, a negative readout would be existential; a positive one could redefine the company. Impact score 7 reflects a high-concentration binary within 6 months but with TTI-109 providing some optionality.
The next major binary event is the TTI-101 Phase 1b/2 HCC topline data in 2H 2026. Monitor for signals of efficacy (objective response rate, progression-free survival) vs. standard of care. The stock is deeply beaten down (~87% off 52-week high) with analyst mean PT implying ~165% upside from ~$3, but cash only runs through Q4 2026, and the S-3 shelf ($200M) creates dilution overhang. This is a high-risk/high-reward binary — position sizing is critical.
Price Chart
Executive Summary
TTI-101 is a first-in-class, oral STAT3 inhibitor being developed by Tvardi Therapeutics (TVRD, ~$3/share, ~$19M market cap) for hepatocellular carcinoma (liver cancer). The drug showed promising Phase 1 data (60% clinical benefit rate, 20% confirmed partial responses in HCC) but suffered a major setback when its Phase 2 IPF trial failed in October 2025, sending the stock down ~84%. All eyes are now on the Phase 1b/2 REVERT LIVER CANCER topline data expected in 2H 2026 — the company's last standing clinical catalyst. With only ~$25M cash runnning through Q4 2026 and a $200M shelf registration creating dilution overhang, this is a high-risk binary. The recent positive TTI-109 (next-gen prodrug) Phase 1 data provides some pipeline optionality but does not solve the near-term funding gap.
How It Works
TTI-101 is a pill that blocks a protein called STAT3, which is overactive in many cancers and drives tumor growth while also suppressing the immune system's ability to fight the cancer. By inhibiting STAT3, the drug aims to both slow tumor growth and restore the immune system's anti-cancer activity.
Trial Status
The REVERT LIVER CANCER Phase 1b/2 trial (NCT05440708) evaluating TTI-101 as monotherapy and in combination with pembrolizumab or atezolizumab + bevacizumab in advanced hepatocellular carcinoma has completed recruitment. Topline data is expected in 2H 2026. Separately, a Phase 2 REVERT IPF trial failed to meet its goals in October 2025 (stock crashed ~84%). A Phase 1 trial in advanced solid tumors (NCT03195699) was completed and published in Clinical Cancer Research (March 2025), showing no dose-limiting toxicities and clinical benefit in 60% of evaluable HCC patients including 20% confirmed partial responses.
The Two-Sided Case
Upcoming Catalysts
- Topline Phase 1b/2 HCC (REVERT LIVER CANCER) data — expected 2H 2026 (the primary binary event)
- Cash runway expiration — Q4 2026; potential equity financing or partnership required thereafter
- TTI-109 Phase 2 initiation in dermatology/GI indications — planned for 2027, subject to IND clearance and additional funding
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Tvardi Therapeutics, Inc. 8-K TVRD ·Originating report